Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Stoke Therapeutics reports Q1 EPS (34c), consensus (36c) » 07:04
05/15/20
05/15
07:04
05/15/20
07:04
STOK

Stoke Therapeutics

$23.84 /

-1.02 (-4.10%)

"I am incredibly…

"I am incredibly gratified by the focus and determination of our employees during these challenging times. Thanks to their unwavering commitment to patients, we are continuing to make progress with STK-001 and are on track to enroll and dose the first children and adolescents with Dravet syndrome in the Phase 1/2a Monarch study later this year," said Edward Kaye, M.D., CEO of Stoke Therapeutics. "Our understanding of the potential for our TANGO technology in additional genetic diseases has continued to advance and we are generating data that we believe will support the nomination of a second preclinical candidate in the second half of 2020."

ShowHide Related Items >><<
STOK Stoke Therapeutics
$23.84 /

-1.02 (-4.10%)

STOK Stoke Therapeutics
$23.84 /

-1.02 (-4.10%)

02/07/20 Guggenheim
Guggenheim starts NeuBase Therapeutics at Buy with $13 price target
12/17/19 Wedbush
Stoke Therapeutics initiated with an Outperform at Wedbush
11/12/19
Fly Intel: Top five analyst initiations
11/12/19 BTIG
Stoke Therapeutics initiated with a Buy at BTIG
STOK Stoke Therapeutics
$23.84 /

-1.02 (-4.10%)

Over a quarter ago
Hot Stocks
Stoke Therapeutics reports FDA confirmation that STK-001 may procede » 08:10
03/23/20
03/23
08:10
03/23/20
08:10
STOK

Stoke Therapeutics

$22.47 /

-0.25 (-1.10%)

"In 2019 we advanced…

"In 2019 we advanced our understanding of the potential applications of our TANGO technology to a variety of genetic targets, and generated preclinical data that underscore our confidence in STK-001 as a promising potential disease-modifying treatment for Dravet syndrome," said Edward M. Kaye, M.D., CEO of Stoke Therapeutics. "As we look ahead to 2020, we are poised to become a clinical-stage company with the anticipated start of our first in-human study of STK-001, and a growing portfolio as we work toward identifying our next preclinical product candidate later this year. The company also provided an update on its lead product candidate, STK-001, for Dravet syndrome. In the first quarter of 2020, Stoke received communication from the FDA confirming that it may proceed with clinical dosing in Part A of its planned Phase 1/2a "Monarch" study of STK-001 in children and adolescents ages 2 to 18 years old with Dravet syndrome. Part A of the study is designed to evaluate two dose cohorts of STK-001. As part of that communication, the FDA also informed the company that it has placed a partial clinical hold on Part B of the study, which is designed to evaluate higher doses of STK-001, pending additional preclinical toxicology data. This partial clinical hold is not due to any identified manufacturing or safety issue. Rather, the FDA is requesting additional preclinical testing to determine the safety profile of doses higher than the current no observed adverse effect level, or NOAEL. The NOAEL was determined using data from a pivotal non-human primate study that evaluated intrathecal delivery of single dose levels of STK-001. The highest dose administered in this study was equivalent to a human dose that is higher than what Stoke plans to administer in Part B of its Phase 1/2a clinical study and did not demonstrate effects that were considered adverse. Stoke has initiated single-dose toxicology studies to more fully characterize the safety profile of STK-001 at higher doses, in order to facilitate the removal of the partial clinical hold and proceed to Part B of the study. At the completion of dosing in Part A, and upon FDA clearance, Stoke will proceed with the higher-dosing cohorts planned in Part B of the study. Stoke still anticipates preliminary data from the study in 2021 and is working to minimize any potential delay to continued clinical testing of STK-001.

ShowHide Related Items >><<
STOK Stoke Therapeutics
$22.47 /

-0.25 (-1.10%)

02/07/20 Guggenheim
Guggenheim starts NeuBase Therapeutics at Buy with $13 price target
12/17/19 Wedbush
Stoke Therapeutics initiated with an Outperform at Wedbush
11/12/19
Fly Intel: Top five analyst initiations
11/12/19 BTIG
Stoke Therapeutics initiated with a Buy at BTIG
Initiation
Guggenheim starts NeuBase Therapeutics at Buy with $13 price target » 07:41
02/07/20
02/07
07:41
02/07/20
07:41
NBSE

NeuBase Therapeutics

$5.93 /

-0.29 (-4.66%)

, WVE

Wave Life Sciences

$7.68 /

+0.27 (+3.64%)

, STOK

Stoke Therapeutics

$29.24 /

+1.16 (+4.13%)

As previously reported,…

As previously reported, Guggenheim analyst Whitney Ijem initiated coverage of NeuBase Therapeutics with a Buy rating and $13 price target. The company's PATrOL platform for the development of ASOs has the potential to address key limitations of current oligo therapeutics and Ijem thinks near-term preclinical proof-of-concept trial results, combined with high profile rare disease indications like Huntington's Disease and DM1, could lead to a valuation more in line with preclinical peers such as Wave Life Sciences (WVE) and Stoke Therapeutics (STOK), the analyst tells investors.

ShowHide Related Items >><<
NBSE NeuBase Therapeutics
$5.93 /

-0.29 (-4.66%)

02/06/20 Guggenheim
NeuBase Therapeutics initiated with a Buy at Guggenheim
11/20/19 Oppenheimer
NeuBase Therapeutics initiated with an Outperform at Oppenheimer
10/29/19 H.C. Wainwright
NeuBase Therapeutics initiated with a Buy at H.C. Wainwright
09/24/19 BTIG
NeuBase Therapeutics initiated with a Buy at BTIG
WVE Wave Life Sciences
$7.68 /

+0.27 (+3.64%)

01/02/20 H.C. Wainwright
H.C. Wainwright cuts Wave Life price target to $20, but 'not throwing in towel'
12/31/19
Fly Intel: Top five analyst actions
12/31/19 Guggenheim
Wave Huntington's data 'mediocre, but not a zero,' says Guggenheim
12/31/19 SunTrust
Wave Life Sciences price target lowered to $20 from $27 at SunTrust
STOK Stoke Therapeutics
$29.24 /

+1.16 (+4.13%)

12/17/19 Wedbush
Stoke Therapeutics initiated with an Outperform at Wedbush
11/12/19
Fly Intel: Top five analyst initiations
11/12/19 BTIG
Stoke Therapeutics initiated with a Buy at BTIG
10/25/19 H.C. Wainwright
Stoke Therapeutics initiated with a Buy at H.C. Wainwright
Options
Ten new option listings and two option delistings on January 23rd » 08:30
01/23/20
01/23
08:30
01/23/20
08:30
AKRO

Akero Therapeutics

$23.34 /

+0.46 (+2.01%)

, AQST

Aquestive Therapeutics

$3.90 /

-0.2 (-4.88%)

, CYCN

Cyclerion Therapeutics

$3.75 /

+0.23 (+6.53%)

, ITRN

Ituran

$25.31 /

-0.51 (-1.98%)

, OBSV

ObsEva

$4.39 /

-0.09 (-2.01%)

, PHAS

PhaseBio

$5.43 /

-0.2 (-3.55%)

, PHAT

Phathom Pharmaceuticals

$38.10 /

+1.29 (+3.50%)

, STOK

Stoke Therapeutics

$23.87 /

+0.52 (+2.23%)

, XP

XP Inc.

$42.45 /

+1.845 (+4.54%)

, MDR

McDermott

$0.70 /

+ (+0.00%)

, TOO

Changed to ALIN

$1.54 /

-0.005 (-0.32%)

New option listings for…

New option listings for January 23rd include Akero Therapeutics Inc (AKRO), Aquestive Therapeutics Inc (AQST), Cyclerion Therapeutics Inc (CYCN), Ituran (ITRN), McDermott International Inc (MDRIQ), ObsEva (OBSV), PhaseBio Pharmaceuticals Inc (PHAS), Phathom Pharmaceuticals Inc (PHAT), Stoke Therapeutics Inc (STOK), and XP Inc (Class A Stock) (XP). Option delistings effective January 23rd include McDermott International Inc (MDR) and Teekay Offshore Partners LP (Units) (TOO).

ShowHide Related Items >><<
AKRO Akero Therapeutics
$23.34 /

+0.46 (+2.01%)

07/15/19 Evercore ISI
Akero Therapeutics initiated with an Outperform at Evercore ISI
07/15/19 Jefferies
Akero Therapeutics initiated with a Buy at Jefferies
07/15/19 JPMorgan
Akero Therapeutics initiated with an Overweight at JPMorgan
07/15/19 Roth Capital
Akero Therapeutics initiated with a Buy at Roth Capital
AQST Aquestive Therapeutics
$3.90 /

-0.2 (-4.88%)

01/13/20 Lake Street
Aquestive competitor approval may bring overhang, says Lake Street
12/27/19 Lake Street
Aquestive Therapeutics price target lowered to $10 from $11 at Lake Street
12/17/19 Wedbush
Aquestive Therapeutics price target lowered to $34 from $37 at Wedbush
12/02/19 JMP Securities
Aquestive Therapeutics NDA filing a positive sign, says JMP Securities
CYCN Cyclerion Therapeutics
$3.75 /

+0.23 (+6.53%)

08/21/19 Spin-Off Research
Cyclerion Therapeutics upgraded to Buy from Hold at Spin-Off Research
06/03/19 Credit Suisse
Cyclerion Therapeutics initiated with a Neutral at Credit Suisse
ITRN Ituran
$25.31 /

-0.51 (-1.98%)

05/16/19 Barclays
Ituran initiated with an Overweight at Barclays
OBSV ObsEva
$4.39 /

-0.09 (-2.01%)

12/19/19 H.C. Wainwright
ObsEva price target raised to $40 from $36 at H.C. Wainwright
12/02/19 H.C. Wainwright
ObsEva price target lowered to $36 from $44 at H.C. Wainwright
11/08/19 Credit Suisse
ObsEva downgraded to Neutral from Outperform at Credit Suisse
07/29/19 Credit Suisse
ObsEva price target lowered to $16 from $24 at Credit Suisse
PHAS PhaseBio
$5.43 /

-0.2 (-3.55%)

01/16/20 Stifel
PhaseBio acquisition of PB6440 an 'excellent' strategic move, says Stifel
12/18/19 Citi
Citi calls PhaseBio most undervalued SMid-Biotech stock
10/03/19 H.C. Wainwright
PhaseBio initiated with a Buy at H.C. Wainwright
09/09/19 Stifel
PhaseBio selloff on prasugrel vs. ticagrelor study 'well overdone,' says Stifel
PHAT Phathom Pharmaceuticals
$38.10 /

+1.29 (+3.50%)

11/19/19 Evercore ISI
Phathom Pharmaceuticals initiated with an Outperform at Evercore ISI
11/19/19
Fly Intel: Top five analyst initiations
11/19/19 Needham
Phathom Pharmaceuticals initiated with a Buy at Needham
11/19/19 Jefferies
Phathom Pharmaceuticals initiated with a Buy at Jefferies
STOK Stoke Therapeutics
$23.87 /

+0.52 (+2.23%)

12/17/19 Wedbush
Stoke Therapeutics initiated with an Outperform at Wedbush
11/12/19
Fly Intel: Top five analyst initiations
11/12/19 BTIG
Stoke Therapeutics initiated with a Buy at BTIG
10/25/19 H.C. Wainwright
Stoke Therapeutics initiated with a Buy at H.C. Wainwright
XP XP Inc.
$42.45 /

+1.845 (+4.54%)

01/06/20 Morgan Stanley
Morgan Stanley starts XP Inc. at Overweight with $45 price target
01/06/20 Morgan Stanley
XP Inc. initiated with an Overweight at Morgan Stanley
01/06/20 JPMorgan
XP Inc. initiated with an Overweight at JPMorgan
01/05/20 Goldman Sachs
XP Inc. initiated with a Neutral at Goldman Sachs
MDR McDermott
$0.70 /

+ (+0.00%)

01/13/20 Bernstein
McDermott initiated with an Underperform at Bernstein
11/05/19 Citi
McDermott bankruptcy risk is rising, Citi says, while cutting target to $1.60
09/20/19 Credit Suisse
McDermott's plans to sell Lummus 'a last resort,' says Credit Suisse
09/19/19 Citi
Citi sees working capital unwind as 'legitimate risk' for McDermott
TOO Changed to ALIN
$1.54 /

-0.005 (-0.32%)

Initiation
Stoke Therapeutics initiated with an Outperform at Wedbush » 16:26
12/17/19
12/17
16:26
12/17/19
16:26
STOK

Stoke Therapeutics

$26.70 /

+1.51 (+5.99%)

Wedbush analyst Laura…

Wedbush analyst Laura Chico initiated coverage of Stoke Therapeutics with an Outperform rating and $31 price target.

ShowHide Related Items >><<
STOK Stoke Therapeutics
$26.70 /

+1.51 (+5.99%)

11/12/19
Fly Intel: Top five analyst initiations
11/12/19 BTIG
Stoke Therapeutics initiated with a Buy at BTIG
10/25/19 H.C. Wainwright
Stoke Therapeutics initiated with a Buy at H.C. Wainwright
07/15/19 Credit Suisse
Stoke Therapeutics initiated with an Outperform at Credit Suisse
Hot Stocks
Stoke Therapeutics presents STK-001 preclinical data in Dravet syndrome » 10:04
12/08/19
12/08
10:04
12/08/19
10:04
STOK

Stoke Therapeutics

$28.91 /

+3.99 (+16.01%)

Stoke Therapeutics…

Stoke Therapeutics presented new preclinical data on STK-001, a potential new disease-modifying medicine for the treatment of Dravet syndrome. Data from studies in non-human primates showed STK-001 distributed throughout the brain and achieved target engagement and increased Nav1.1 protein expression throughout the cortex after a single intrathecal injection, the company said. Safety findings showed STK-001 to be well-tolerated at the two intrathecal dose levels studied, it added. These data were presented today in a poster session at the American Epilepsy Society Annual Meeting in Baltimore. Stoke selected two dose levels of STK-001 for this non-GLP study in order to evaluate safety, brain biodistribution, target engagement and Nav1.1 protein expression. On day 1, treatment-naive cynomolgus monkeys were administered a single, bolus intrathecal lumbar injection at one of two dose levels of STK-001. After dosing, the animals underwent standard clinical and neurological observation, and blood samples were collected. STK-001 concentration level, gene expression, and protein expression were assessed in the brain on day 3 and on day 29. Brain tissue exposure to STK-001 was observed on day 3 and day 29. In the high dose group, exposure of STK-001 was observed in all brain regions examined, except pons and thalamus. STK-001 levels in cortical brain regions were generally higher than in deeper structures and were also increased from day 3 to day 29.

ShowHide Related Items >><<
STOK Stoke Therapeutics
$28.91 /

+3.99 (+16.01%)

11/12/19
Fly Intel: Top five analyst initiations
11/12/19 BTIG
Stoke Therapeutics initiated with a Buy at BTIG
10/25/19 H.C. Wainwright
Stoke Therapeutics initiated with a Buy at H.C. Wainwright
07/15/19 Credit Suisse
Stoke Therapeutics initiated with an Outperform at Credit Suisse
Hot Stocks
Stoke Therapeutics presents preclinical data from studies of STK-001 » 12:13
12/07/19
12/07
12:13
12/07/19
12:13
STOK

Stoke Therapeutics

$28.91 /

+3.99 (+16.01%)

Stoke Therapeutics…

Stoke Therapeutics announced preclinical data from studies of STK-001 "that showed significant improvements in survival and reductions in seizure frequency in a mouse model of Dravet syndrome." New data from electroencephalography recordings showed 76% of DS mice treated with STK-001 were seizure free compared to 48% that were treated with a placebo, the company said in a statement. An 80% reduction in the average number of spontaneous seizures was also observed among treated DS mice compared to placebo. These data were presented in a poster session at the American Epilepsy Society Annual Meeting in Baltimore. "The data on STK-001 from this mouse model give us confidence in our approach to treating the underlying cause of Dravet syndrome by restoring Nav1.1 protein expression to near normal levels," said Edward Kaye, Chief Executive Officer of Stoke Therapeutics. "The reductions in mortality previously observed with STK-001 were compelling and the new EEG data provide further evidence of the potential for STK-001 to impact Dravet syndrome by reducing seizure frequency and possibly preventing seizures entirely. What is particularly remarkable is that these data were generated from a spontaneous seizure model, which we believe accurately reflects the clinical situation in people with Dravet syndrome."

ShowHide Related Items >><<
STOK Stoke Therapeutics
$28.91 /

+3.99 (+16.01%)

11/12/19
Fly Intel: Top five analyst initiations
11/12/19 BTIG
Stoke Therapeutics initiated with a Buy at BTIG
10/25/19 H.C. Wainwright
Stoke Therapeutics initiated with a Buy at H.C. Wainwright
07/15/19 Credit Suisse
Stoke Therapeutics initiated with an Outperform at Credit Suisse
Initiation
Fly Intel: Top five analyst initiations » 10:16
11/12/19
11/12
10:16
11/12/19
10:16
ARLO

Arlo Technologies

$2.84 /

+0.18 (+6.77%)

, CCC

Clarivate Analytics

$17.22 /

+0.13 (+0.76%)

, STOK

Stoke Therapeutics

$30.87 /

+1.04 (+3.49%)

, BMRN

BioMarin

$75.96 /

+0.72 (+0.96%)

, BIIB

Biogen

$291.50 /

-2.41 (-0.82%)

, AMGN

Amgen

$223.35 /

+2.66 (+1.21%)

, CTVA

Corteva

$27.06 /

+0.32 (+1.20%)

Catch up on today's…

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Arlo Technologies (ARLO) resumed with a Buy at Deutsche Bank. 2. Clarivate Analytics (CCC) initiated with a Hold at Stifel. 3. Stoke Therapeutics (STOK) initiated with a Buy at BTIG. 4. BioMarin (BMRN), Biogen (BIIB), and Amgen (AMGN) were initiated with a Buy at SunTrust. 5. Corteva (CTVA) initiated with a Buy at Redburn. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
ARLO Arlo Technologies
$2.84 /

+0.18 (+6.77%)

11/11/19 Deutsche Bank
Arlo Technologies resumed with a Buy at Deutsche Bank
02/27/19 Imperial Capital
Arlo Technologies activist likely to obtain board seat, says Imperial Capital
02/06/19 Imperial Capital
Arlo Technologies price target lowered to $7.50 from $29 at Imperial Capital
02/06/19
Fly Intel: Top five analyst downgrades
CCC Clarivate Analytics
$17.22 /

+0.13 (+0.76%)

11/11/19 Stifel
Clarivate Analytics initiated with a Hold at Stifel
07/18/19
Fly Intel: Top five analyst initiations
07/18/19 Citi
Clarivate Analytics initiated with a Neutral at Citi (yesterday)
05/17/19 B. Riley FBR
Clarivate Analytics initiated with a Buy at B. Riley FBR
STOK Stoke Therapeutics
$30.87 /

+1.04 (+3.49%)

11/12/19 BTIG
Stoke Therapeutics initiated with a Buy at BTIG
10/25/19 H.C. Wainwright
Stoke Therapeutics initiated with a Buy at H.C. Wainwright
07/15/19 Credit Suisse
Stoke Therapeutics initiated with an Outperform at Credit Suisse
07/15/19 Cowen
Stoke Therapeutics initiated with an Outperform at Cowen
BMRN BioMarin
$75.96 /

+0.72 (+0.96%)

11/12/19 SunTrust
BioMarin initiated with a Buy at SunTrust
10/30/19 Citi
BioMarin price target lowered to $95 from $120 at Citi
10/28/19 Canaccord
BioMarin price target lowered to $108 from $117 at Canaccord
10/25/19 Wedbush
BioMarin price target raised to $152 from $128 at Wedbush
BIIB Biogen
$291.50 /

-2.41 (-0.82%)

11/12/19 SunTrust
Biogen initiated with a Buy at SunTrust
11/01/19 Standpoint Research
Biogen downgraded to Hold from Buy at Standpoint Research
10/30/19
Fly Intel: Top five analyst upgrades
10/30/19 Bernstein
Biogen upgraded to Outperform from Market Perform at Bernstein
AMGN Amgen
$223.35 /

+2.66 (+1.21%)

11/12/19 SunTrust
Amgen initiated with a Buy at SunTrust
11/05/19
Fly Intel: Top five analyst upgrades
11/05/19 Cantor Fitzgerald
Amgen upgraded to Overweight from Neutral at Cantor Fitzgerald
11/04/19 Maxim
BeiGene price target raised to $210 from $170 at Maxim
CTVA Corteva
$27.06 /

+0.32 (+1.20%)

11/12/19 Redburn
Corteva initiated with a Buy at Redburn
11/05/19 Spin-Off Research
Corteva downgraded to Hold from Buy at Spin-Off Research
11/01/19 JPMorgan
JPMorgan downgrades Corteva to Neutral, cuts target to $27 from $30
11/01/19 JPMorgan
Corteva downgraded to Neutral from Overweight at JPMorgan
Initiation
Stoke Therapeutics initiated with a Buy at BTIG » 06:20
11/12/19
11/12
06:20
11/12/19
06:20
STOK

Stoke Therapeutics

$29.83 /

-0.17 (-0.57%)

BTIG analyst Thomas…

BTIG analyst Thomas Shrader initiated coverage of Stoke Therapeutics with a Buy rating and $46 price target. The analyst cites the potential of the company's technology built by the inventors of SPINRAZA, along with the large informatics engine designed to identify additional disease states that might be treated via modification of pre-mRNA splicing. The "systematic screening methodology called TANGO" has nearly "boundless potential" toward treating a large number of genetic diseases and likely many chronic diseases, Shrader writes in his research note.

ShowHide Related Items >><<
STOK Stoke Therapeutics
$29.83 /

-0.17 (-0.57%)

10/25/19 H.C. Wainwright
Stoke Therapeutics initiated with a Buy at H.C. Wainwright
07/15/19 Credit Suisse
Stoke Therapeutics initiated with an Outperform at Credit Suisse
07/15/19 Cowen
Stoke Therapeutics initiated with an Outperform at Cowen
07/15/19 Canaccord
Stoke Therapeutics initiated with a Buy at Canaccord
Initiation
Stoke Therapeutics initiated with a Buy at H.C. Wainwright » 07:09
10/25/19
10/25
07:09
10/25/19
07:09
STOK

Stoke Therapeutics

$23.13 /

+0.05 (+0.22%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Debjit Chattopadhyay initiated coverage of Stoke Therapeutics with a Buy rating and $30 price target. The analyst believes TANGO, an antisense oligonucleotide platform, is an "intriguing approach" at combating haploinsufficiencies.

ShowHide Related Items >><<
STOK Stoke Therapeutics
$23.13 /

+0.05 (+0.22%)

07/15/19 Credit Suisse
Stoke Therapeutics initiated with an Outperform at Credit Suisse
07/15/19 Cowen
Stoke Therapeutics initiated with an Outperform at Cowen
07/15/19 Canaccord
Stoke Therapeutics initiated with a Buy at Canaccord
07/15/19 JPMorgan
Stoke Therapeutics initiated with an Overweight at JPMorgan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.